Liraglutide suppresses postprandial triglyceride & apolipoprotein B48

Liraglutide treatment in patients with type 2 diabetes significantly reduced postprandial excursions of triglyceride and apolipoprotein B48 after a fat-rich meal, independently of gastric emptying. Results indicate liraglutide’s potential to reduce cardiovascular disease risk via improvement of postprandial lipaemia (Diabetes, Obesity and Metabolism)